Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Aschenbrenner DS – The FDA has requested that the product labeling for leukotriene inhibitors include a precaution that neuropsychiatric events have been reported in some patients taking the drugs. The agency is advising health care providers and patients to be aware that these reported adverse effects might occur.

Related Articles

MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: Synergistic action with LY294002, an inhibitor of phosphatidylinositol 3?-kinase
Cancer Letters, 11/16/09    Relevance Score: 80%

Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor
Journal of Experimental Medicine, 10/28/09    Relevance Score: 80%

Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4
Rheumatology International, 10/27/09    Relevance Score: 80%

Leukotriene B4 Contributes to Exhaled Breath Condensate and Sputum Neutrophil Chemotaxis in COPD
Chest, 10/14/09    Relevance Score: 80%

Targeting Leukotrienes for the Treatment of COPD
Inflammation & Allergy - Drug Targets, 10/12/09    Relevance Score: 80%

Today in Neuro/Psych pharmacology...keeping you current

Modafinil for multiple sclerosis fatigue: Does it work
Clinical Neurology and Neurosurgery, 12/18/09

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry in six countries
Current Medical Research and Opinion, 12/18/09

Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders
Phytotherapy Research, 12/18/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address